TriSalus Life Sciences is a new company record. Its research profile isn't ready yet.
trisaluslifesci.comCrawled Oct 30, 2026
Nelitolimod (SD-101), a TLR9 agonist, is being studied to reactivate the immune system in the liver and pancreas.
TriSalus’ clinical trials are studying treatments to improve the outcomes of patients with liver and pancreatic tumors.
TriSalus’ drug delivery devices are based on the proprietary PEDD method, which has been shown to improve delivery of therapeutic agents.
This web page serves as notice under 35 U.S.C. §287(a) that the following TriSalus product may be covered by one or more of the following US patents.
Immunosuppressive MDSCs are recruited to the tumor microenvironment. TLR9 agonists have been shown to reprogram and eliminate MDSCs, reducing their
Myeloid-derived suppressor cells in the liver and liver tumors, and intratumoral pressure, limit the efficacy of immunotherapy.
Pancreatic tumors are highly fibrotic and have high immunosuppressive cell infiltration, limiting the efficacy of immunotherapy.
The page lists scientific publications and presentations by TriSalus scientists and clinical collaborators.
DENVER and CHICAGO, May 10, 2022 – TriSalus Life Sciences, an immunotherapy company on a mission to extend and improve the lives of patients living with
Immunotherapeutic collaboration will advance efforts to develop new treatment options for patients with liver and pancreatic tumors
New data from PERIO-01 clinical trial indicates PEDD method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA)
Join a team of innovative and dedicated employees committed to making a difference in the lives of patients suffering from solid tumors.
At TriSalus, everyone has a shared purpose: to extend and improve the lives of patients living with liver and pancreatic tumors.
About TriSalus:
David Patience was appointed Chief Financial Officer beginning in July 2025.
Mary Szela, Chief Executive Officer and President
Mary Szela, Chief Executive Officer, President, Director of TriSalus.
Mr. Stansky was a Managing Director of Tudor Investment Corporation where he was responsible for long/short equity, crossover, and venture capital
TriSalus has a singular purpose—to help more patients with liver and pancreatic tumors benefit from immunotherapy treatments.
Contact TriSalus for general inquiries, investor relations, sales support, clinical trials information, and media relations.
The page describes partnerships with TriSalus to develop immunotherapy combinations for patients.
TriSalus integrates delivery technology with standard therapies and immunotherapy to improve outcomes for solid tumor patients.
TriSalus Life Sciences has adopted a code of conduct to address interactions involving health care professionals with respect to its products and services
The page provides access to the Early Access to TriSalus Investigational Products Policy.
The policy explains how TriSalus treats personal information on its websites and related portals.
